Cell and gene therapy (CGT) delivery is a challenge for every provider organization that invests in these revolutionary treatments. Given the high cost of CGT treatments, financial sustainability is especially hard to achieve. The complexity of these treatments also makes it difficult to determine where stakeholders should invest. Whether launching a new program or expanding an existing one, health systems can use the tools, worksheets, and case studies included in this playbook to make smarter decisions about CGT delivery and reimbursement.